CAR T-Cell Therapy in Hematological Malignancies
Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility compl...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2021-08, Vol.22 (16), p.8996 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 16 |
| container_start_page | 8996 |
| container_title | International journal of molecular sciences |
| container_volume | 22 |
| creator | Haslauer, Theresa Greil, Richard Zaborsky, Nadja Geisberger, Roland |
| description | Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hematological malignancies such as acute myeloid leukemia (AML) remains difficult. In this review, we focus especially on CAR T-cell application in different hematological malignancies as well as strategies for overcoming CAR T-cell dysfunction and increasing their efficacy. |
| doi_str_mv | 10.3390/ijms22168996 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8396650</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2566042451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-2638f75dd675505fa58270efbb5a027413d1c8f58964d2313f2348d2be7abf213</originalsourceid><addsrcrecordid>eNpdkc1Lw0AQxRdRbP24eZaAFw9Gd2c_klyEEtQKFUHqedkku-2WJFt3G6H_vSmtpXqagfnxZt48hK4Ivqc0ww920QQAItIsE0doSBhAjLFIjg_6AToLYYExUODZKRpQxhhPMBkinI8-ommc67qOpnPt1XId2TYa60atXO1mtlR19KZqO2tVW1odLtCJUXXQl7t6jj6fn6b5OJ68v7zmo0lcMgKrGARNTcKrSiScY24UTyHB2hQFVxgSRmhFytTwNBOsAkqoAcrSCgqdqMIAoefocau77IpGV6VuV17Vculto_xaOmXl30lr53LmvmVKMyE47gVudwLefXU6rGRjQ9n7VK12XZDAhcAMGN_suvmHLlzn296eBAE9QwQWPXW3pUrvQvDa7I8hWG6ikIdR9Pj1oYE9_Pt7-gNaYYKL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624241606</pqid></control><display><type>article</type><title>CAR T-Cell Therapy in Hematological Malignancies</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Haslauer, Theresa ; Greil, Richard ; Zaborsky, Nadja ; Geisberger, Roland</creator><creatorcontrib>Haslauer, Theresa ; Greil, Richard ; Zaborsky, Nadja ; Geisberger, Roland</creatorcontrib><description>Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hematological malignancies such as acute myeloid leukemia (AML) remains difficult. In this review, we focus especially on CAR T-cell application in different hematological malignancies as well as strategies for overcoming CAR T-cell dysfunction and increasing their efficacy.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms22168996</identifier><identifier>PMID: 34445701</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acute myeloid leukemia ; Antigen (tumor-associated) ; Antigen presentation ; Antigens ; Antigens, Neoplasm - immunology ; Blood ; Cancer therapies ; CD19 antigen ; Cell therapy ; Chimeric antigen receptors ; Disease ; FDA approval ; Hematologic Neoplasms - metabolism ; Hematologic Neoplasms - pathology ; Hematologic Neoplasms - therapy ; Hematology ; Humans ; Immunotherapy ; Immunotherapy - methods ; Immunotherapy, Adoptive - methods ; Immunotherapy, Adoptive - trends ; Kinases ; Leukemia ; Leukemia - immunology ; Leukemia - therapy ; Lymphatic leukemia ; Lymphocytes B ; Lymphocytes T ; Lymphoma ; Lymphoma - immunology ; Lymphoma - therapy ; Major histocompatibility complex ; Medical prognosis ; Monoclonal antibodies ; Multiple myeloma ; Patients ; Receptors, Antigen, T-Cell - immunology ; Receptors, Chimeric Antigen - immunology ; Remission (Medicine) ; Response rates ; Review ; Stem cells ; T-Lymphocytes - immunology ; Transplants & implants ; Tumors</subject><ispartof>International journal of molecular sciences, 2021-08, Vol.22 (16), p.8996</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-2638f75dd675505fa58270efbb5a027413d1c8f58964d2313f2348d2be7abf213</citedby><cites>FETCH-LOGICAL-c412t-2638f75dd675505fa58270efbb5a027413d1c8f58964d2313f2348d2be7abf213</cites><orcidid>0000-0002-4462-3694 ; 0000-0002-8331-0922 ; 0000-0002-0131-2191 ; 0000-0002-9775-185X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396650/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396650/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34445701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haslauer, Theresa</creatorcontrib><creatorcontrib>Greil, Richard</creatorcontrib><creatorcontrib>Zaborsky, Nadja</creatorcontrib><creatorcontrib>Geisberger, Roland</creatorcontrib><title>CAR T-Cell Therapy in Hematological Malignancies</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hematological malignancies such as acute myeloid leukemia (AML) remains difficult. In this review, we focus especially on CAR T-cell application in different hematological malignancies as well as strategies for overcoming CAR T-cell dysfunction and increasing their efficacy.</description><subject>Acute myeloid leukemia</subject><subject>Antigen (tumor-associated)</subject><subject>Antigen presentation</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Blood</subject><subject>Cancer therapies</subject><subject>CD19 antigen</subject><subject>Cell therapy</subject><subject>Chimeric antigen receptors</subject><subject>Disease</subject><subject>FDA approval</subject><subject>Hematologic Neoplasms - metabolism</subject><subject>Hematologic Neoplasms - pathology</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Immunotherapy, Adoptive - trends</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia - immunology</subject><subject>Leukemia - therapy</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma - immunology</subject><subject>Lymphoma - therapy</subject><subject>Major histocompatibility complex</subject><subject>Medical prognosis</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Patients</subject><subject>Receptors, Antigen, T-Cell - immunology</subject><subject>Receptors, Chimeric Antigen - immunology</subject><subject>Remission (Medicine)</subject><subject>Response rates</subject><subject>Review</subject><subject>Stem cells</subject><subject>T-Lymphocytes - immunology</subject><subject>Transplants & implants</subject><subject>Tumors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1Lw0AQxRdRbP24eZaAFw9Gd2c_klyEEtQKFUHqedkku-2WJFt3G6H_vSmtpXqagfnxZt48hK4Ivqc0ww920QQAItIsE0doSBhAjLFIjg_6AToLYYExUODZKRpQxhhPMBkinI8-ommc67qOpnPt1XId2TYa60atXO1mtlR19KZqO2tVW1odLtCJUXXQl7t6jj6fn6b5OJ68v7zmo0lcMgKrGARNTcKrSiScY24UTyHB2hQFVxgSRmhFytTwNBOsAkqoAcrSCgqdqMIAoefocau77IpGV6VuV17Vculto_xaOmXl30lr53LmvmVKMyE47gVudwLefXU6rGRjQ9n7VK12XZDAhcAMGN_suvmHLlzn296eBAE9QwQWPXW3pUrvQvDa7I8hWG6ikIdR9Pj1oYE9_Pt7-gNaYYKL</recordid><startdate>20210820</startdate><enddate>20210820</enddate><creator>Haslauer, Theresa</creator><creator>Greil, Richard</creator><creator>Zaborsky, Nadja</creator><creator>Geisberger, Roland</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4462-3694</orcidid><orcidid>https://orcid.org/0000-0002-8331-0922</orcidid><orcidid>https://orcid.org/0000-0002-0131-2191</orcidid><orcidid>https://orcid.org/0000-0002-9775-185X</orcidid></search><sort><creationdate>20210820</creationdate><title>CAR T-Cell Therapy in Hematological Malignancies</title><author>Haslauer, Theresa ; Greil, Richard ; Zaborsky, Nadja ; Geisberger, Roland</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-2638f75dd675505fa58270efbb5a027413d1c8f58964d2313f2348d2be7abf213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute myeloid leukemia</topic><topic>Antigen (tumor-associated)</topic><topic>Antigen presentation</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Blood</topic><topic>Cancer therapies</topic><topic>CD19 antigen</topic><topic>Cell therapy</topic><topic>Chimeric antigen receptors</topic><topic>Disease</topic><topic>FDA approval</topic><topic>Hematologic Neoplasms - metabolism</topic><topic>Hematologic Neoplasms - pathology</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Immunotherapy, Adoptive - trends</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia - immunology</topic><topic>Leukemia - therapy</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma - immunology</topic><topic>Lymphoma - therapy</topic><topic>Major histocompatibility complex</topic><topic>Medical prognosis</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Patients</topic><topic>Receptors, Antigen, T-Cell - immunology</topic><topic>Receptors, Chimeric Antigen - immunology</topic><topic>Remission (Medicine)</topic><topic>Response rates</topic><topic>Review</topic><topic>Stem cells</topic><topic>T-Lymphocytes - immunology</topic><topic>Transplants & implants</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haslauer, Theresa</creatorcontrib><creatorcontrib>Greil, Richard</creatorcontrib><creatorcontrib>Zaborsky, Nadja</creatorcontrib><creatorcontrib>Geisberger, Roland</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haslauer, Theresa</au><au>Greil, Richard</au><au>Zaborsky, Nadja</au><au>Geisberger, Roland</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAR T-Cell Therapy in Hematological Malignancies</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2021-08-20</date><risdate>2021</risdate><volume>22</volume><issue>16</issue><spage>8996</spage><pages>8996-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hematological malignancies such as acute myeloid leukemia (AML) remains difficult. In this review, we focus especially on CAR T-cell application in different hematological malignancies as well as strategies for overcoming CAR T-cell dysfunction and increasing their efficacy.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34445701</pmid><doi>10.3390/ijms22168996</doi><orcidid>https://orcid.org/0000-0002-4462-3694</orcidid><orcidid>https://orcid.org/0000-0002-8331-0922</orcidid><orcidid>https://orcid.org/0000-0002-0131-2191</orcidid><orcidid>https://orcid.org/0000-0002-9775-185X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2021-08, Vol.22 (16), p.8996 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8396650 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Acute myeloid leukemia Antigen (tumor-associated) Antigen presentation Antigens Antigens, Neoplasm - immunology Blood Cancer therapies CD19 antigen Cell therapy Chimeric antigen receptors Disease FDA approval Hematologic Neoplasms - metabolism Hematologic Neoplasms - pathology Hematologic Neoplasms - therapy Hematology Humans Immunotherapy Immunotherapy - methods Immunotherapy, Adoptive - methods Immunotherapy, Adoptive - trends Kinases Leukemia Leukemia - immunology Leukemia - therapy Lymphatic leukemia Lymphocytes B Lymphocytes T Lymphoma Lymphoma - immunology Lymphoma - therapy Major histocompatibility complex Medical prognosis Monoclonal antibodies Multiple myeloma Patients Receptors, Antigen, T-Cell - immunology Receptors, Chimeric Antigen - immunology Remission (Medicine) Response rates Review Stem cells T-Lymphocytes - immunology Transplants & implants Tumors |
| title | CAR T-Cell Therapy in Hematological Malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A10%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAR%20T-Cell%20Therapy%20in%20Hematological%20Malignancies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Haslauer,%20Theresa&rft.date=2021-08-20&rft.volume=22&rft.issue=16&rft.spage=8996&rft.pages=8996-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms22168996&rft_dat=%3Cproquest_pubme%3E2566042451%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624241606&rft_id=info:pmid/34445701&rfr_iscdi=true |